

8<sup>th</sup> Health Informatics in Africa Conference (HELINA 2013) Peer-reviewed and selected under the responsibility of the Scientific Programme Committee

# Adequacy and Quality of Immunization Data in a Comprehensive Electronic Health Record System

Aggrey Keny<sup>a\*</sup>, Paul Biondich<sup>b,c</sup>, Shaun Grannis<sup>b,c</sup>, Martin C. Were<sup>b,c</sup>

<sup>a</sup>REACH Informatics, Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya <sup>b</sup>Regenstrief Institute Inc. <sup>c</sup>Indiana University School of Medicine, Indianapolis, Indiana, USA

**Background and Purpose:** Timely, simultaneous and combined vaccination is important to protect children from common infectious diseases. In a large health care delivery system in Western Kenya, we examined the adequacy and quality of data within the electronic health record (EHR) to assess the feasibility of developing a clinical decision support system to improve childhood vaccination uptake and coverage.

**Methods:** The study evaluated vaccination information collected and stored in an EHR between 2006 and 2012 involving 23,270 children. Encounters for 10,299 children lacked immunization information and were excluded.

**Results:** Documentation of vaccination coverage and timeliness is rendered in Kaplan–Meier time-toevent plots. Vaccination coverage at the end of one year ranges from 60% to 90% for all vaccines assessed individually that are part of the Kenya Expanded Program on Immunization (KEPI). Timely documentation of vaccination is low, with 52.8 weeks (95% CI: 52.1, 53.5) for measles vaccine and 29.2 weeks (95% CI: 28.5, 29.8) for the Bacillus Calmette–Guérin (BCG) vaccine. Complete vaccine observations were recorded in 16% of the encounters. Combination and simultaneous vaccine administration had high congruence and consistency.

**Conclusion:** A clinical decision support system that generates reminders to clinicians and caretakers of children would optimize vaccination uptake and improve overall immunization coverage. To achieve this, immunization data in the EHR must be timely, complete and consistent. Assessed vaccination timeliness is low, despite high coverage. Vaccine observations are often incomplete. There is need to improve the data collection process to achieve data quality levels that can adequately support a clinical decision support system.

Keywords: Vaccination, Electronic health records, Developing countries, Data quality

# 1 Introduction

Throughout the world, the use of vaccines has helped to save many lives. The Expanded Program on Immunization, created in 1974, is considered one of the world's most successful public health initiatives of the 20th century [1]. The Global Alliance for Vaccines and Immunization, which supports vaccination programs in developing countries, estimates that by 2010 its work supporting vaccination helped avert approximately 5 million pediatric deaths worldwide [2]. Vaccination programs have proven to be highly cost effective, and are important in achieving Millennium Development Goal 4, which calls for reduction by two-thirds of under-5 mortality by 2015[3]. In developing countries, vaccination programs also form a fundamental part of the healthcare systems. This is because vaccination sessions provide additional opportunities to deliver other health care services that might otherwise be missed, including treatment for malnutrition, malaria, intestinal worms, growth monitoring, breast feeding education, among others [4].

\*Corresponding author: REACH Informatics, Academic Model Providing Access to Healthcare (AMPATH), P. O. Box 9157 Eldoret, 30100, Kenya. Email: agris57@yahoo.com, Tel: +254-722-571562

HELINA 2013 M. Korpela et al. (Eds.)

<sup>© 2013</sup> HELINA and JHIA. This is an Open Access article published online by JHIA and distributed under the terms of the Creative Commons Attribution Non-Commercial License. DOI: 10.12856/JHIA-2013-v1-i1-40

Beyond individual benefits of vaccination, herd immunity can also be achieved when adequate numbers of children are immunized for the particular condition.

In developing countries, immunization information is often collected along with other clinical information as part of routine clinical care for the child. In these cases, the immunization information becomes part of the child's longitudinal record. Well-functioning immunization programs need reliable record systems to assist providers in offering timely and high quality immunization care. These records should include details about a child's prior vaccinations, immunizations administered on a particular visit, and the administration dates for all vaccinations [5]. The same individual immunization data can be aggregated and used by administrators and Ministries of Health in health services planning and to inform healthcare policies. With increasing adoption of Electronic Health Records (EHRs) in developing countries, immunization data is increasingly being stored in an electronic format as part of a longitudinal electronic record [6]. When available electronically, immunization information can potentially be leveraged to deliver automatic reminders and alerts for upcoming or missed immunizations. The immunization information stored can also be aggregated in various ways to best serve the needs of decision-makers at multiple levels.

To best serve the clinical purpose, immunization records need to be part and parcel of the patient's comprehensive record and available to clinicians when needed. As such, cases of isolated immunization databases, often seen as part of some immunization campaigns, rarely reflect the reality of the child's comprehensive clinical record.

EHRs are oftentimes touted as leading to more accurate, timely and readily available data than traditional paper systems [7]. However, almost no research exists to inform on the adequacy with which immunization information collected as part of routine care within EHRs in developing countries actually meet the needs for high quality immunization care [8]. In this study, we critically evaluate the quality and usefulness of child immunization data collected as part of routine clinical visits in a large comprehensive care program in Western Kenya. We particularly focus on how well this data reflects the real picture of immunization services provided, and whether the data passes 'fitness for use' test to inform decisions at individual and systemic levels.

# 2 Methods

#### 2.1 Study setting

This study was conducted in a large care program formed by the partnership between United States Agency for International Development (USAID) and the Academic Model Providing Access to Healthcare (AMPATH) in Western Kenya [9]. Established in 2001, the AMPATH program is one of the largest comprehensive care programs in sub-Saharan Africa, serving a catchment area of over 2 million individuals through 30 parent and 49 satellite clinical sites. The program offers a broad range of services from antenatal care, pediatric and adult primary care services, HIV care and chronic disease management programs.

At AMPATH clinics, childhood immunizations are offered as per the Kenya Expanded Programme on Immunization (KEPI) schedule, with each child completing routine immunizations in five encounters [10]. The immunizations administered as part of the KEPI schedule are as follows: At Birth - Bacillus Calmette-Guerin (BCG) and Oral Polio (Polio 0); At 6, 10 and 14 weeks of age the children receive Oral Polio, Pentavalent, and Pneumococcal Conjugate vaccines at each of these visits. Measles vaccine is administered last at the age of 9 months. Pentavalent vaccine is a combination vaccine comprised of Diptheria, Pertusis, Tetanus (DPT), Hemophilus influenza Type B (HIB) and Hepatitis B (Hep B) vaccines.

#### 2.2 Immunization Records

Since 2004, AMPATH clinics have used the AMPATH Medical Record System (AMRS) to store comprehensive, longitudinal electronic patient records for all enrolled patients [11]. AMRS is the original implementation of OpenMRS, an open-source electronic health record system deployed widely in the developing world [12]. Clinicians caring for AMPATH patients do not enter data directly into AMRS but rather complete paper encounter forms that contain clinical parameters and categorical observations

previously defined and encoded into the AMRS concept dictionary (see Appendix A for pediatric encounter form). Where necessary, clinicians can write down diagnoses, test results, and other observations as free-text if these are not included in checklists on the encounter form. Clerks with basic computer skills and minimal medical knowledge enter data from the encounter forms into the AMRS. The encounter forms are then placed in the patient's paper clinic chart, which is available to the clinician during patient care.

At AMPATH, immunization information is collected within pediatric encounter forms by clinicians at every visit (Appendix A & **Fig. 1**). Immunization information collected include all previous immunizations (**Fig. 1** – Item 32a), whether the child is on schedule with immunizations or not (**Fig. 1** – Item 32b), and the exact immunizations administered during the visit (**Fig. 1** – Item 51e).

	◎ HIB	Dose#: 0 1 0 2 0 3	0	BCG					
Pentavalent	O DPT	Dose#: 1 2 3	0	Measles	Dose#:	01			
Vaccine	HEP B	Dose#: 0 1 0 2 0 3	0	Polio	Dose#:	0 1	0 2	3	0
	Completed	All O Unknown							
2b. Are immuniz	1. P.H. 1	edule? 🔘 Yes 🔘 No 🔘 Unk	nown						
2b. Are immuniz	ations on sch	edule? Ves No Unk							
2b. Are immuniz	ations on sch ns Ordered To HIB	edule? 🔘 Yes 🔘 No 🔘 Unk	mown						
	ations on sch s Ordered To HIB t DPT	edule? Ves No Unk		s Dos	se #: © 1				

Fig. 1. Sections of routine clinical encounter form that capture immunization information for a child

#### 2.3 Study Population

This study involved evaluation of immunization data collected for all children enrolled in the AMPATH program clinics and born between January 2006 and December 2010 as represented on **Fig. 2**.



Fig. 2. Study population

#### 2.4 Data Collection

All immunization information for the cohort of children in the study was collected in the paper encounter forms, and the data entered into the AMRS EHR. We used data in the EHR from January 1, 2006 to 31

<sup>© 2013</sup> HELINA and JHIA. This is an Open Access article published online by JHIA and distributed under the terms of the Creative Commons Attribution Non-Commercial License. DOI: 10.12856/JHIA-2013-v1-i1-40

March 2012. These dates were chosen because the oldest children in the cohort were born in January 2006, whereas the youngest were born in December 2010. By looking at data until March 2012, we felt comfortable that the youngest children in the study cohort would be expected to have completed the required immunization as per the schedule. For each of the study participants, we extracted demographic information and for each clinical encounter, we extracted historical immunization information, and the vaccine types and value of dose administered.

IRB approval was obtained from the Institutional Research and Ethics Committee at Moi University School of Medicine, Eldoret, Kenya, and Indiana University's Institutional Review Board in Indianapolis, Indiana. All data was de-identified before analysis.

## 2.5 Outcome measures

The goal of this study was to assess the data quality and adequacy of immunization data collected within the EHR to satisfy the needs of a clinical decision support system aimed at improving immunization in the relevant population. Data quality dimensions that are generally accepted as depicting the real world scenarios are accuracy, timeliness, completeness, precision and consistency [13]-[17]. As pertains to immunization data quality, these dimensions have been refined in the General Recommendation on Immunization [18]. Since these redefined dimensions are better at ascertaining the accuracy and adequacy of immunization data, we chose to apply these in our analysis. These are:

- 1. Timeliness. Age appropriate administration of vaccines as recommended based on demonstrated efficacy and safety for specific age groups at risk of experiencing the disease. Timely vaccinations induce adequate immunity.
- **2.** Spacing of the multiple sources of the same antigen. Optimal immune response is achieved when doses of the same vaccine are administered at recommended intervals.
- **3.** Simultaneous administration. Administering more than one vaccine on the same clinic day, at different anatomic sites, and not combined in the same syringe. There is adequate scientific basis for simultaneously administering all vaccines for which a child is eligible at the time of a visit and this increases the probability of age appropriate compliance.
- **4.** Combination vaccines. Combination vaccines merge equivalent component vaccines into single products to prevent more than one disease or to protect against multiple strains of infectious agents causing the same disease. This also reduces the number of injections patients receive and alleviates concerns associated with the number of injections.

#### 2.6 Data analysis

MYSQL was used to extract the data from AMRS and analysis was done in SPSS version 19. The analyses were confined to 23,270 children aged 15 - 75 months (born between 1 January 2006 and 31 December 2010) excluding 10,299 children due to missing vaccination information. A reference date of 31 March 2012 was set for age calculations and vaccination observations made after this date were excluded.

Age appropriate vaccination uptake (timeliness) was estimated by the Kaplan-Meier method with age in weeks as the timescale [19][20]. Vaccination coverage at age t was estimated by 1 - SKM (t), the Kaplan-Meier survival function; 1 - SKM (t) is the cumulative probability of being vaccinated by age t. Comparison of survival distribution from cohort to cohort was carried out using Log Rank and Tarone-Ware techniques [21].

# 3 Results

A total of 23,270 eligible children (49.3% male, 50.7% female), aged 15 - 75 months in a total of 272,926 encounters and 1,258,348 immunization observations comprising 5 birth cohorts were included in the study period from 1 January 2006 to 31 March 2012. 10,299 children did not have any immunization data collected during this period. The mean age for the study subjects was 42 months (SD 17.4). The distribution of children in the cohorts is 3,125 in 2006; 3,848 in 2007; 4,095 in 2008; 5,359 in 2009 and 6,843 in 2010 cohorts.

<sup>© 2013</sup> HELINA and JHIA. This is an Open Access article published online by JHIA and distributed under the terms of the Creative Commons Attribution Non-Commercial License. DOI: 10.12856/JHIA-2013-v1-i1-40

Kaplan-Meier estimates show an overall systematic reduction in the mean time of recording of the first immunization observation over time towards the recommended age of vaccine administration. This trend is best demonstrated by measles observations with a mean time of 38.240 (95% CI: 37.728, 38.751) weeks against the recommended age of 36 weeks in the last cohort (2010), however the overall mean time throughout the 5 cohorts is slightly higher, 52.804 (95% CI: 52.147,53.462). The first vaccine in the schedule, BCG, takes longer to be administered or recorded in the system with a mean overall time of 29.162 (95% CI: 28.482, 29.841) weeks, but this interval reduces over time through the cohorts (**Fig. 3** and **Fig. 4**).

The time course of completion of BCG and DPT series vaccinations is described graphically in **Fig. 3**.It is evident that for both BCG and DPT the series completion of primary vaccination is achieved by only about 10% of the children by the recommended time of 14 weeks at most, and it takes another 300 weeks for all children to have the vaccine observations recorded.



Fig. 3. Age at recording of vaccine observations presented in Kaplan–Meier plots (inverse and cumulative) for BCG and DPT. The X-axis is the age in weeks (used in KEPI schedule) and the Y-axis is the proportion of vaccine observations at each time point. The red vertical lines indicate the recommended age for vaccination. Age of one year is indicated as a scaling (green vertical dotted line), and is the age when all the vaccines are required to have been completed.



Fig. 4. Age at recording of vaccine observations presented in Kaplan–Meier plots (inverse and cumulative) for Oral Polio and Measles

Up to 80% of all children have their observations recorded by their first birthdays, demonstrated by steeper survival curves. After the first year, the curves generally plateau off and it takes much longer for the remaining children to have their vaccine observations administered or recorded. This also explains why most vaccine coverage estimations in the region are found to be about 80%; since age one year is usually taken as the benchmark for a fully immunized child, against a global recommendation of 90% [22]. This commonly used approach is disadvantageous since vaccination coverage can only be determined for the preset age groups and it is not possible to establish the age at which the defined coverage levels are achieved [20]. The multiple dose vaccines such as DPT and Polio reach the 80% mark within the recommended age of 6 weeks for the first doses in both vaccines. The subsequent doses show less steep curves and reach 80 % after longer time intervals.

Test of equality of survival distributions for the different vaccine and different birth cohorts using Log Rank (Mantel-Cox) and Breslow (Generalized Wilcoxon) methods found significant differences between cohort pairs and overall comparisons. This means that the timeliness of vaccine administration and observation changes over the years; with a systematic improvement from 2006 to 2010 as demonstrated by differences in gradients of the graphs.

In the year 2011, the total number of pentavalent component vaccine observations (DPT,Hep B and HIB) were the highest throughout the study period. During this time, this combination vaccine had a concurrence of 97.4% for the 3 vaccine components. This is expected since these vaccines are administered from the same vial. There was no significant difference between the individual vaccine observations (

Fig. 5).



Fig. 5. Relationship of combination vaccine components for immunization observations in 2011.

Based on the recommendation that all age-appropriate doses of vaccines be administered simultaneously to children for whom no specific contraindications exist at the time of the visit, **Fig. 6** depicts the relationship between Polio and DPT observations through the 5 cohorts [18]. The proportions of DPT observations range from 48.1% to 50.0% while Polio observations range from 50.0% to 51.9% through the 5 cohorts. There are no significant differences between these proportions at alpha 0.05 levels as demonstrated by the overlapping 95% CI bars in the first two cohorts. Polio 0, administered at birth for children born in health facilities, estimated at 40% of all deliveries, contributes to the slightly higher polio observations in the last 3 cohorts, since DPT is not administered at this time [23]. In these 3 cohorts, the 95% CI do not overlap and thus the differences are significant.



Fig. 6. DPT/Polio Observations showing simultaneous administration

**Fig. 7** shows an output from the EHR. Each vaccine represented is incomplete and it is not possible to know how far the child is in the vaccination schedule. This is a direct consequence of having 2 checkboxes for each vaccine as clinicians often tick one of the two required places. When they tick only the checkbox with the vaccine type, the system will store that vaccine type without the dosage, and when they only tick the checkbox with dosage, the system stores a value without a corresponding vaccine type. This is a very common phenomenon and

**Table 1** shows exactly how this applies to other vaccines for the study duration. Most vaccines have doses 1-3 and polio has 0-4.

9.	IMMUNIZAT	ION HISTORY
	PREVIOUS IMMUNIZATIONS ADMINISTERED	NUMBER OF DOSES RECEIVED BEFORE ENROLLMENT
		4.0
		1.0
	BACILLE CAMILE-GUERIN VACCINATION	
		3.0

Fig. 7. Sample output from AMPATH Medical Record System.

Table 1. Completeness of immunization data for multiple dose	vaccines
--	----------

						VACCIN	E TYPE						
			DPT	Hep B	Polio	HIB	Pneumovax	Penta	PCV 10	Missing	Total		
Dose	0	Count	N/A	N/A	<i>798</i>	N/A	N/A	N/A	N/A	935	1,794		
value		%			0.4%					2.7%	0.2%		
	1	Count	5,391	3,593	5,534	3,623	10	1	19	8,318	26,428		
		%	2.9%	2.0%	2.9%	2.0%	3.8%	0.5%	9.7%	24.3%	3.5%		
	2	Count	5,252	3,445	5,556	3,445	9	4	41	5,407	23,159		
		%	2.9%	1.9%	2.9%	1.9%	3.4%	2.1%	20.9%	15.8%	3.0%		
	3	Count	13,111	11,087	5,850	11,099	211	171	128	17,060	58,717		
		%	7.1%	6.2%	3.1%	6.2%	<b>79.6</b> %	90.0%	65.3%	<b>49.9</b> %	7.7%		
	4	Count	N/A	N/A	8,975	N/A	N/A	N/A	N/A	2,495	11,470		
		%			4.7%					7.3%	1.5%		
	Missing	Count	160,422	159,609	163,630	159,761	35	14	8		643,479		
		%	87.1%	89.8%	86.0%	<b>89.8</b> %	13.2%	7.4%	4.1%		84.1%		
Total		Count	184,176	177,734	190,343	<i>177,92</i> 8	265	190	196	34,215	765,047		

#### 4 Discussion

A fully immunized child is one who has received all the recommended immunizations within the first one year of life as per the KEPI schedule. This commonly used measure of the proportion of children with specific immunization types at defined ages ('up-to-date') lacks the flexibility of measuring immunization compliance over time and often gives lower compliance figures. EHRs allow visualization of

108

immunization compliance over time. Kaplan-Meier survival plots enable graphic visualization of vaccination at any chosen time interval [20].

Measuring immunization compliance at specific ages recommended for particular vaccine administration and at the age of 1 year showed significantly low rates compared to the overall rates achieved at the end of the study period. This could be explained in two ways; delays in vaccine administration and information system time lag between vaccine administration and recording [24]. Actual delays in vaccine administration are common in the setting where this study was carried out and there are many shortfalls in the healthcare system and personal factors that result in this. Identified characteristics of a well-functioning vaccination systems that promote timely vaccination include availability of health services at all times, short distances and waiting times, media promotion and campaigns [24]. The time intervals between vaccine administration and recording into the EHR vary, and could affect calculation of compliance rates when these intervals are large because vaccine observations are recorded on the date of encounter and not the date of administration.

In the 5 cohorts, there is a general trend of improvement in compliance rates at the age appropriate intervals as time progresses. Whereas the compliance rate of BCG in 2006 is about 60% at the age of one year, it is over 90% in 2010 at the same age. The EHR was relatively new in 2006 and clinicians and other users were still getting used to use it. This phase of learning involves not only getting used to the new encounter forms and workflows, but also disrupts routine tasks and interrupts existing workflows in the healthcare processes with record keeping and data quality falling behind the previous schedules [25]. By 2010, extensive use of the encounter forms and full integration into the workflows resulted in marked improvements in timeliness and therefore, compliance rates. This is important because timely vaccination aside from good coverage, offers better protection from diseases such as Pertussis, Measles and Haemophilus Influenzae type B [26]-[28]. However, we do not know for sure whether the changes in timeliness are due to changes in the recording process or healthcare administrative processes because the system records vaccine observations as per encounter dates and not administration dates. To adequately address this phenomenon, we will carry out another analysis after redesigning the encounter form to take into consideration human and system factors that affect vaccine data quality.

Other studies have found similar differences between up-to date and age-appropriate vaccination [20] [29]. However, in this study care must be taken when evaluating compliance across time because data delay and ongoing processes yield incomplete data and comparison at face value may not be fully valid. In addition, there are logistical challenges such as failure to store sufficient vaccine stocks at all times, poor cold chain system maintenance, and inadequate staffing at health facilities that further reduce compliance rates [30].

Simultaneous and combined vaccine administrations were found to have high consistencies and concurrence among the various affected vaccine observations. This is associated not only with reduced number of injections, but also improves the main target of vaccination programs: timely and complete protection [31].

Findings from this study are mostly consistent with other reports on analysis of EHRs. While EHRs provide a versatile means of information storage and access, there are associated deficiencies in clinical and managerial applications [25]. There are many reasons for this, ranging from people dynamics to electronic tools. In relatively new systems, like the AMRS, the learning process is still taking place. The data collection forms and processes are initially still being refined and the personnel are getting used to the new system. Completeness was found to have the lowest data quality across all data variables (

**Table 1**). We found that providers often did not complete the immunization fields as required in the forms. They would check the vaccine type and leave out the dose and vice versa. This made it difficult to calculate the spacing between different doses of the same antigen, as this requires vaccine type and dosage values to be present.

Decision support tools are important in promoting structured data entry and other determinants of data quality [16]. Since data entry is a tedious process and consumes a considerable amount of clinicians' and data entry clerks' time, it would be efficient to collect only new and relevant data during every encounter. The design of the encounter forms plays a significant role in data quality. 10,299 (30.1%) of the children had missing immunization observations attributable to the encounter type used in this group. The Rural Health Centre Encounter form does not have the section on 'previous immunizations' and only collects 'ordered' (given today) immunization observations (See appendix 2), which directly contributes to significant missing data.

As a result of this evaluation, the encounter form has been significantly improved to take into consideration human factors that affect data quality and effective data collection processes. The immunization sections on the redesigned encounter forms are depicted on **Fig. 8**. In this design, the separation of vaccines and dosages has been eliminated and these now appear as one combined tickable checkbox for each vaccine given. Combined vaccine Pentavalent is now represented as one vaccine instead of individual components. The arrangement also corresponds to the KEPI schedule and it is convenient for clinicians to check all vaccines in a row that are given at the same time.

10I. Previous Imr	munizations:	None 🗆	Completed Schedule			
BCG	Polio 0					
Penta 1	Polio 1		D PCV 1	Rotavirus 1		Uitamin A (children
Penta 2	🗆 Polio 2		D PCV 2	□ Rotavirus 2_ (g	iven before 6 months)	under tive only)
Penta 3	🗆 Polio 3		D PCV 3	Measles 0 (6mo)	nths)	(9months)
10m.Immunizatio	ons confirmed fro	om card ם א	es □ No	•		
40. Immunizations	Ordered Today	None	Completed Schedule	9		
🗆 BCG	Polio 0					
D Penta 1	Polio 1	D PCV 1	Rotavirus 1			
Penta 2	Polio 2	D PCV 2	🗆 Rotavirus 2 🧃	iven before 6 months)	Ditamin A (childre	en under live only)
Penta 3	Polio 3	D PCV 3	Measles 0 (6mo)	nths)	(9months)	

Fig. 8. Immunization section on redesigned AMPATH pediatric encounter form

#### 4.1 Limitations

Generalizability of these findings is limited to settings with similar characteristics. The study uses vaccine observation times rather than administration times.

In some cases, it may be justified to postpone vaccination temporarily when children are moderately or severely ill. Vaccination is then recommended to be given soon after recovery. This was not assessed nor analyzed.

# 5 Conclusion

Data quality is affected by many factors involving data collection, storage and retrieval. Development of a clinical decision support system that generates reminders directed at clinicians and parents with immunization eligible children would optimize vaccination uptake and improve overall immunization coverage. This study found low age-appropriate vaccination status and high overall vaccination coverage which implies that vaccine administration and recording into the EHR are not timely. Many children were unprotected by vaccination for several months despite being vaccinated at the end of follow-up. The data collection through ticking of checkboxes on paper encounter forms contributes to incomplete data when clinicians fail to tick all the required checkboxes. To achieve data quality levels adequate for a clinical decision support, data collection processes need to be improved through form redesign and clinician sensitization.

### References

- Centers for Disease Control and Prevention (US). Ten Great Public Health Achievements--United States, 1900-1999.MMWR Recomm Rep.1999; 48(12): p. 241.
- [2] GAVI. GAVI Alliance Progress Report 2010. 2010.
- [3] UNICEF. A World Fit for Children. Proceedings of the Millennium Development Goals; Special Session on Children Documents; The Convention on the Rights of the Child Conference; 2002 July; New York, US. New York, US: UNICEF;2002
- [4] Wolfson LJ, Gasse F, Lee-Martin SP, Lydon P, Magan A, Tibouti A, Johns B, Hutubessy R, Salama P, Okwo-Bele JM. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. B World Health Organ, 2008; 86(1): p. 27-39.
- [5] Stevens LA, Palma JP, Pandher KK, Longhurst CA. Immunization registries in the EMR Era. Online J Public Health Inform, 2013; 5(2): p. 211.

- [6] Williams F,Boren SA. The role of the electronic medical record (EMR) in care delivery development in developing countries: a systematic review. Inform Prim Care, 2008; 16(2): p. 139-145.
- [7] Ndira SP, Rosenberger KD, Wetter T. Assessment of data quality of and staff satisfaction with an electronic health record system in a developing country (Uganda): a qualitative and quantitative comparative study. Methods Inf Med, 2008; 47(6): p. 489-98.
- [8] Weiner JP, Fowles JB, Chan KS. New paradigms for measuring clinical performance using electronic health records. Int J Qual Health Care 2012; 24(3): p. 200-5.
- [9] Einterz RM, Kimaiyo S, Mengech HN, Khwa-Otsyula BO, Esamai F, Quigley F, Mamlin JJ. Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med, 2007; 82(8): p. 812-8.
- [10] Bjerregaard P. [Vaccination of children in Kenya]. Ugeskr Laeger, 1989; 151(48): p. 3221-5.
- [11] Tierney WM, Rotich JK, Hannan TJ, Siika AM, Biondich PG, Mamlin BW, Nyandiko WM, Kimaiyo S, Wools-Kaloustian K, Sidle JE, et al. The AMPATH medical record system: creating, implementing, and sustaining an electronic medical record system to support HIV/AIDS care in western Kenya. Stud Health Technol Inform, 2007; 129(Pt 1): p. 372-6.
- [12] Mamlin BW, Biondich PG, Wolfe BA, Fraser H, Jazayeri D, Allen C, Miranda J, Tierney WM. Cooking up an open source EMR for developing countries: OpenMRS - a recipe for successful collaboration. AMIA Annu Symp Proc, 2006: p. 529-33.
- [13] Batini C, Cappiello C, Francalanci C, Maurino A. Methodologies for data quality assessment and improvement. ACM Comput. Surv., 2009; 41(3): p. 1-52.
- [14] Wand Y,Wang RY. Anchoring data quality dimensions in ontological foundations. Commun. ACM, 1996; 39(11): p. 86-95.
- [15] Wang RY, Strong DM. Beyond accuracy: what data quality means to data consumers. J. Manage. Inf. Syst., 1996; 12(4): p. 5-33.
- [16] Liaw ST, Taggart J, Dennis S, Yeo A. Data quality and fitness for purpose of routinely collected data--a general practice case study from an electronic practice-based research network (ePBRN). AMIA Annu Symp Proc, 2011; 2011: p. 785-94.
- [17] Pipino LL, Lee YW, Wang RY. Data quality assessment. Commun. ACM, 2002; 45(4): p. 211-218.
- [18] Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization.MMWR: Morbidity & Mortality Weekly Report.2011; 60(2): p. 1-64.
- [19] Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method). BMJ, 1998; 317(7172): p. 1572.
- [20] Laubereau B, Hermann M, Schmitt HJ, Weil J, von Kries R. Detection of delayed vaccinations: a new approach to visualize vaccine uptake. Epidemiol Infect, 2002; 128(2): p. 185-92.
- [21] Wakounig S, Heinze G, Schemper M. Non-parametric estimation of relative risk in survival and associated tests. Stat Methods Med Res, 2011.
- [22] Centers for Disease Control and Prevention (US). Global routine vaccination coverage, 2010.MMWR Recomm Rep.2011; 60: p. 1520-2.
- [23] Izugbara C, Ezeh A, Fotso JC. The persistence and challenges of homebirths: perspectives of traditional birth attendants in urban Kenya. Health Policy Plan, 2009; 24(1): p. 36-45.
- [24] Niederhauser VP, Markowitz M. Barriers to immunizations: Multiethnic parents of under- and unimmunized children speak. J Am Acad Nurse Pract, 2007; 19(1): p. 15-23.
- [25] Gillies A. Assessing and improving the quality of information for health evaluation and promotion. Methods Inf Med, 2000; 39(3): p. 208-12.
- [26] von Kries RBOWA. Haemophilus influenzae b-vaccination: the urgency for timely vaccination. European Journal of Pediatrics, 1997; 156(4): p. 282.
- [27] Grant CC, Roberts M, Scragg R, Stewart J, Lennon D, Kivell D, Ford R, Menzies R. Delayed immunisation and risk of pertussis in infants: unmatched case-control study. BMJ, 2003; 326(7394): p. 852-3.
- [28] The National Vaccine Advisory Committee. The measles epidemic. The problems, barriers, and recommendations. JAMA Pediatr.1991; 266(11): p. 1547-52.
- [29] Dayan GH, Shaw KM, Baughman AL, Orellana LC, Forlenza R, Ellis A, Chaui J, Kaplan S, Strebel P. Assessment of delay in age-appropriate vaccination using survival analysis. Am J Epidemiol, 2006; 163(6): p. 561-70.
- [30] Fadnes LT, Nankabirwa V, Sommerfelt H, Tylleskar T, Tumwine JK, Engebretsen IM. Is vaccination coverage a good indicator of age-appropriate vaccination? A prospective study from Uganda. Vaccine, 2011; 29(19): p. 3564-70.
- [31] Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J, 2006; 25(6): p. 507-12.

# Appendix A: AMPATH Pediatric Clinical Encounter Form

USAID AMPATH	PAEDIATRIC I	RETURN VISIT FOR	
PARTNERSHIP			/ /
1.Name:	AN	IPATH ID:	Previous ID:
			Mother's AMPATH ID
2. DOB: / / 3. Mother Deceased:YesNoUnk	Age: Yrs.		cheduled Early  Unscheduled Late
Father deceased: DYes No DUnki		4. Li Suleduled Li Olis	creduled Larry 13 onscreduled Late
5. Clinic Location:		6. Category:	7. Person Bringing Patient:
MTRH Module: 01 0 2 0 3 0 4 Chulaimbo 0 1		D Pilot DMTCT Plus DNASCOP DSelf Pay	Mother Father Sibling
Amukura     Burnt Forest     Iten     Kabarnet     Khunyangu     Kitale     Mosoriot     Mt. Eigon			Grandparent P M
DUG District Hospital D Webuye D Moi's Bridge		oResearch oOther:	
Nambale = Mukhobola = Bumala	A		Children's home Other
o Satelite: o Other.	0 Deviews I	mmunizations: DBCG	
8. Current Feeding: tick all that apply Breast Dormula Cow's/Ani			sles Dose#: □1
Expressed Breast milk Other liqu			Dose#: 01 02 03 04
Water Solid Foo			npleted all Dunknown
10. If breastfeeding, is mother on ARVs?		Siblings < 18 months?	
□Yes □No □Unknown		they registered in Pediatric PATH ID's: 1.	HIV clinic?  Yes No Unknown 2.
12. Child's Current HIV Status: DHIV ex			
13. Has patient been hospitalized since			
14. Does Child have a disability?   Ye			
15. Current Medications:			
15a. ARVs: Ves No Is this the patie			ARV's: DpMTCT D Clinical disease
3TC (4mg/kg): Syrupmgm     d4T (1mg/kg): Tabs15203	allabs mg CK	ABC (8mg/kg): Syru	p mgmi □iabs mg p mgmi □Tabs mg
□ AZT: (180mg/m2): □ Syrupmg_			
□ NVP: □ Syrupmgml □Ta	bs mg 🛛	Nelfinavir: D Po	wder mg Tabs mg
EFV: Syrupmgml DTa	bs mg	Other: Syru	p ml
15b. PCP Prophylaxis: None Sept			
15d. TB Treatment:  None Comp Rifampicin INH Pyrazinam		) CRifater CRifinah	
15e.Cryptococcus Tx: None Diflu		15f.Other Drugs:	te of TD deadlent/
16. Adherence:			
16a. Who has been giving the medicine t			
16a. Who has been giving the medicine t Mother Father Sibling Grandparer	nt Auntie OUncle D	Self Children's Home	Dother (Specify):
16a. Who has been giving the medicine t Mother Father Sibling Grandparer 16b. During the last month has the patier	nt DAuntie DUncle D nt missed any medication	Self Children's Home	DOther (Specify):
16a. Who has been giving the medicine t Mother Father Sibling Grandparer	nt DAuntie DUncle D nt missed any medication	Self Children's Home	D0ther (Specify):
16a. Who has been giving the medicine t Mother □Father □Sibling □Grandparer 16b. During the last month has the patier □ ARVS □ PCP Prophylaxis Drug(s) Missed: 16c. During the last seven days how mar	nt DAuntie DUncle D nt missed any medicati TB Prophylaxis Reason: ny of his/her pills did th	Self Children's Home ons? I Yes I No Anti-TB Medication e patient take?	
16a. Who has been giving the medicine t         Mother       □Father       □Sibling       □Grandparer         16b. During the last month has the patien       □ ARVS       □ PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         □ ARVS:       □ None	ht DAuntie DUncle D ht missed any medicati TB Prophylaxis Reason: hy of his/her pills did th Few Dalf	Self Children's Home ons? Yes No Anti-TB Medication e patient take?	(s) missed
16a. Who has been giving the medicine t         Mother       □Father       □Sibling       □Grandparer         16b. During the last month has the patien       □ ARVS       □ PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         □ ARVS:       □ None         □ PCP Prophylaxis:       □ None	nt DAuntie DUncle D nt missed any medicati TB Prophylaxis Reason: ny of his/her pills did th Few Half Few Half	Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug	(s) missed (s) missed
16a. Who has been giving the medicine t         Mother       □Father       □Sibling       □Grandparer         16b. During the last month has the patien       □ ARVS       □ PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         □ ARVS:       □ None         □ PCP Prophylaxis:       □ None         □ TB Prophylaxis:       □ None	ht DAuntie DUncle D ht missed any medicati TB Prophylaxis Reason: hy of his/her pills did th Few Dalf	Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug	(s) missed (s) missed (s) missed
16a. Who has been giving the medicine t         Mother       □Father       □Sibling       □Grandparer         16b. During the last month has the patier       □ ARVS       □ PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         □ ARVS:       □ None         □ PCP Prophylaxis:       □ None         □ PCP Prophylaxis:       □ None         □ TB Prophylaxis:       □ None         □ Anti-TB Medication:       □ None         □ Anti-TB Medication:       □ None	nt DAuntie DUncle d nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did th Few Half Few Half Few Half Few Half	Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug	(s) missed (s) missed
16a. Who has been giving the medicine t         Mother       □Father       □Sibling       □Grandparer         16b. During the last month has the patier       □ ARVS       □ PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         □ ARVS:       □ None         □ PCP Prophylaxis:       □ None         □ TB Prophylaxis:       □ None         □ TB Prophylaxis:       □ None         □ Anti-TB Medication:       □ None	nt DAuntie DUncle d nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did th Few Half Few Half Few Half Few Half	Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug	(s) missed (s) missed (s) missed
16a. Who has been giving the medicine t         Mother       □Father       □Sibling       □Grandparer         16b. During the last month has the patien       □ ARVS       □ PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         □ ARVS:       □ None         □ PCP Prophylaxis:       □ None         □ TB Prophylaxis:       □ None         □ TB Prophylaxis:       □ None         □ Anti-TB Medication:       □ None         17. Does the patient have any interval comparison	nt DAuntie DUncle d nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did th Few Half Few Half Few Half Few Half	Self Children's Home ons? Yes No Anti-TB Medication e patient take? Most All Drug Most All Drug Most All Drug Most All Drug No	(s) missed
16a. Who has been giving the medicine t         Mother       □Father       □Sibling       □Grandparer         16b. During the last month has the patien       □ ARVS       □ PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         □ ARVS:       □ None         □ PCP Prophylaxis:       □ None         □ TB Prophylaxis:       □ None         □ TB Prophylaxis:       □ None         □ Anti-TB Medication:       □ None         17. Does the patient have any interval comparison	nt missed any medication nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did the Few Half Few Half Few Half Few Half Few Half Months continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       All       Drug         Most       All       Drug         Wost       All       Drug         No       O       O	(s) missed
16a. Who has been giving the medicine t         Mother       □Father       □Sibling       □Grandparer         16b. During the last month has the patien       □ ARVS       □ PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         □ ARVS:       □ None         □ PCP Prophylaxis:       □ None         □ TB Prophylaxis:       □ None         □ TB Prophylaxis:       □ None         □ Anti-TB Medication:       □ None         □ Anti-TB Medication:       □ None         □ Anti-TB Medication:       □ None         □ Diarrhea:       □ days       □ weeks	nt missed any medication nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did th Few Half Few Half Few Half Few Half mplaints? Yes M Months continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       All         e patient take?       Drug         Most       All       Drug         No       Cough:       days	(s) missed (s) missed (s) missed (s) missed (s) missed (s) weeks   Months   Continuous
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         ARVS:       None         PCP Prophylaxis:       None         TB Prophylaxis:       None         ARTB Medication:       None         ARTB Medication:       None         ARTB Medication:       None         Anti-TB Medication:       None         Diarrhea:       days       weeks         Abdominal pain:       days       weeks         Difficulty breathing:       days       weeks	nt missed any medication nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did th Few Half Few Half Few Half Few Half mplaints? Yes M Months continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       All       Drug         Most       All       Drug         No       All       Drug         No       Cough:       days         G       Cough:       days         Fever:       days	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       PCP Prophylaxis       None         16c. During the last seven days how mar       ARVS:       None         2 ARVS:       None       PCP Prophylaxis:       None         16 PCP Prophylaxis:       None       ARt-TB Medication:       None         17 Does the patient have any interval or       Diarrhea:       days       weeks         2 Abdominal pain:       days       weeks       Difficulty breathing:       days       weeks	nt missed any medication nt missed any medication TB Prophylaxis Reason: Ty of his/her pills did the Few Half Few Half Few Half Few Half Months continuous Months Continuous Months Continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       All       Drug         Most       All       Drug         No       Cough:       days         E       Cough:       days         E       Ear discharge:       days	(s) missed (s) missed (s) missed (s) missed (s) missed (weeks   Months   Continuous (weeks   Months   Continuous (weeks   Months   Continuous (s) weeks   Months   Continuous (s) missed (s)
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         ARVS:       None         PCP Prophylaxis:       None         PCP Prophylaxis:       None         ARUS:       None         PCP Prophylaxis:       None         Anti-TB Medication:       None         Anti-TB Medication:       None         Diarrhea:       days       weeks         Diffculty breathing:       days       weeks         Sore throat:       days       weeks         Skin rash:       days       weeks	nt insed any medication in the sed any medication in the sed any medication in the sed any medication in the sed any medic	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       Anti-TB Medication         e patient take?       Most       All         Most       All       Drug         No       Cough:       days         G       Cough:       days         G       Ear discharge:       days         G       Swelling(specify)	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         ARVS:       None         PCP Prophylaxis:       None         PCP Prophylaxis:       None         TB Prophylaxis:       None         Anti-TB Medication:       None         Diarrhea:       days       weeks         Diarrhea:       days       weeks         Difficulty breathing:       days       weeks         Sore throat:       days       weeks         Skin rash:       days       weeks	Auntie Uncle and medication     TB Prophylaxis     Reason:     Reason:     Few Half     Few Half     Few Half     Few Half     Months continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       Anti-TB Medication         e patient take?       Most       All         Most       All       Drug         No       Cough:       days         G       Cough:       days         Fever:       days         Ear discharge:       days	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         ARVS:       None         PCP Prophylaxis:       None         PCP Prophylaxis:       None         ARUS:       None         PCP Prophylaxis:       None         Anti-TB Medication:       None         Anti-TB Medication:       None         Diarrhea:       days       weeks         Diffculty breathing:       days       weeks         Sore throat:       days       weeks         Skin rash:       days       weeks         Other (specify)	Auntie Uncle and medication     TB Prophylaxis     Reason:     Reason:     Few Half     Few Half     Few Half     Few Half     Months continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       Anti-TB Medication         e patient take?       Most       All         Most       All       Drug         No       Cough:       days         G       Cough:       days         G       Ear discharge:       days         G       Swelling(specify)	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar         ARVS:       None         PCP Prophylaxis:       None         PCP Prophylaxis:       None         TB Prophylaxis:       None         Anti-TB Medication:       None         Diarrhea:       days       weeks         Diarrhea:       days       weeks         Difficulty breathing:       days       weeks         Sore throat:       days       weeks         Skin rash:       days       weeks	nt Overlage Sector Sect	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       Anti-TB Medication         e patient take?       Most       All         Most       All       Drug         No       Cough:       days         G       Cough:       days         G       Ear discharge:       days         G       Swelling(specify)	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar       ARVS:       None         PCP Prophylaxis:       None       PCP Prophylaxis:       None         PCP Prophylaxis:       None       ARUS:       None         PCP Prophylaxis:       None       Anti-TB Medication:       None         Anti-TB Medication:       None       Anti-TB Medication:       None         Diarrhea:       days       weeks       Diarrhea:       days       weeks       Diarrhea:         Difficulty breathing:       days       weeks       Diarrhea:       days       weeks       Diarrhea:	Muntie Uncle      Indie Strate     TB Prophylaxis     Reason:     Reason:     roy of his/her pills did th     Few Half     Few Half     Few Half     Few Half     Months Continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication         e patient take?         Most       All       Drug         Image: Cough:       days         Cough:       days         Ear discharge:       days         Secords:       Swelling(specify)         Other (specify)	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       None       PCP Prophylaxis:       None	Muntie Uncle      Indie Sed any medication     TB Prophylaxis     Reason:     To of his/her pills did th     Few Half     Few Half     Few Half     Months continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       Anti-TB Medication         e patient take?       Most       All         Most       All       Drug         No       Cough:       days         Cough:       days       Ear discharge:         Ear discharge:       days         Swelling(specify)       Other (specify)         Interception       Rash         Abnormal       CV	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar       ARVS:       None	Muntie Uncle      Indie Strate     TB Prophylaxis     Reason:     Reason:     roy of his/her pills did th     Few Half     Few Half     Few Half     Few Half     Months Continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       Anti-TB Medication         e patient take?       Most       All         Most       All       Drug         No       Cough:       days         Cough:       days       Ear discharge:         Ear discharge:       days         Swelling(specify)       Other (specify)	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       None       PCP Prophylaxis:       None	Muntie Uncle      Indie Sed any medication     TB Prophylaxis     Reason:     To of his/her pills did th     Few Half     Few Half     Few Half     Months continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       Anti-TB Medication         e patient take?       Most       All         Most       All       Drug         No       Cough:       days         Cough:       days       Ear discharge:         Ear discharge:       days         Swelling(specify)       Other (specify)         Interception       Rash         Abnormal       CV	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar       ARVS:       None	Muntie Uncle      Indie Sed any medication     TB Prophylaxis     Reason:     To of his/her pills did th     Few Half     Few Half     Few Half     Months continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       Anti-TB Medication         e patient take?       Most       All         Most       All       Drug         No       Cough:       days         Cough:       days       Ear discharge:         Ear discharge:       days         Swelling(specify)       Other (specify)         Interception       Rash         Abnormal       CV	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar       ARVS:       None	Muntie Uncle      Indie Sed any medication     TB Prophylaxis     Reason:     To of his/her pills did th     Few Half     Few Half     Few Half     Months continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       Anti-TB Medication         e patient take?       Most       All         Most       All       Drug         No       Cough:       days         Cough:       days       Ear discharge:         Ear discharge:       days         Swelling(specify)       Other (specify)         Interception       Rash         Abnormal       CV	(s) missed
16a. Who has been giving the medicine t         Mother       Father       Sibling       Grandparer         16b. During the last month has the patien       ARVS       PCP Prophylaxis         Drug(s) Missed:       16c. During the last seven days how mar       ARVS:       None	Months   Continuous	Self       Children's Home         ons?       Yes       No         Anti-TB Medication       Anti-TB Medication         e patient take?       Most       All         Most       All       Drug         No       Cough:       days         Cough:       days       Ear discharge:         Ear discharge:       days         Swelling(specify)       Other (specify)         Interception       Rash         Abnormal       CV	(s) missed

19. Test Results: (Please rec Test	Result	Tes	Ludie I	Test	Resul		Test D	ate
WBC/mm <sup>3</sup>				CD4				
Hgb g/dL				CD8				
MCV				CD4%				
Platelets/ mm <sup>3</sup>				HIV Long Elisa			_	
ALC/ mm <sup>3</sup> SGPT		-		HIV DNA PCR	_		-	
Creat mmol/L		_		Viral Load Other:	_			
CXR: Code:				Codes: 0-normal 1-Pi	Efficien 2	-Infiltrate	e 3-MI	
CAR. CODE.				4-Diffuse abn/non-miliary				
20. Current Pediatric Staging		0.00	10					
CDC Class: O N O A O B	D C	Criteria			New Stage	res	□ No	
WHO Stage: 0 1 0 2 0 3	D 4	Criteria			New Stage	Yes	No No	
Not-applicable:  HIV negative	ve 🗆 H	IV Exposed.	status indet	erminate				č
Tuberculosis:				21d. If diagnosed, TB	Diagnosis wa	s done	on basis of	
21a. Household member diagno: 21b. Has the patient been diagno				Household contact FTT/weight loss Suggestive CXR		Chronic	cough (> 2	weeks)
Yes No	Useu wiui	TO SINCE UN	e last visit	CYP			ent rever	
21c. Have you diagnosed this ch	ild with T	B today?		TST positive 'D Ke	ith lones scor	over D p	Other (s	necify):
□ Yes □ No □ Already on ar		e today.		*     Edward Keith score		Pafer to	the manual	Decity).
22. ARV Side-effects/Toxicity:		le effects at	tributable to	ARV since the last vi	sit2 Vec	No	are manual	1
If yes, tick all that apply:	Rash a A	nemia n Li	po-dystrophy	Hepatitis o Neuro	pathy n IRIS	D Ster	ven-Johnson	syndrome
	Lactic Aci	dosis 🗆 D	iarrhoea 🗆	Persistent Vomiting	Other (specify	):		
23. Diagnosis: New Diagnosis	(* Tick "A	dd" to add to	summary s	heet. Tick "Remove" to	delete to from	n summ	nary sheet)	
Diagnosis	New	Ongoing	Resolved	Diagnosis		New	Ongoing	Resolv
1.				3.				
2.		0	Ω	4.				
24. Plan: 24a. ARVs: None Start ARV				-05				- 200
d4T (1mg/kg): : □ Tabs     AZT: (180mg/m2): □ Syrup     NVP: □ Syrupmg     EFV: □ Syrupmg     24b. PCP Prophylaxis: □ None	m ml ml	_mi □Tabs 20 □ 30 mg gmi □ iTabsm Tabsmg art □ Co	Tabs m ng I C	Nelfinavir: Other: nen D Change Reg	Syrup : Syrup Powder	mg	miTa miTa T; Stop	bsm
d4T (1mg/kg): : □ Tabs     AZT: (180mg/m2): □ Syrup     NVP: □ Syrupmg_     EFV: □ Syrupmg_     24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose New Drugs: □ Septrintab 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose:	mg ml ml st control s/day or Comp Weig	_ml □Tabs 20 □ 30 mg gml □ ITabsn Tabsmg art □ Co ity (Specify) ml/day Start INH leted ht Change	Tabs m ng ntinue Regin / D. Co Toxicity Other	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: men Change Reg Weight Change apsone mg/day ntinue INH R (Specify)	□Syrup □ Syrup □ Powder imen □ Re □ Other e-dose □ Acti rug Dose: □	mgmgmgmgmgmg	_mi _Ta mi _Ta T; Stop  NHH 	bs m bs m abs m
d4T (1mg/kg): : □ Tabs     AZT: (180mg/m2): □ Syrup     NVP: □ Syrupmg     EFV: □ Syrupmg 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: New Drugs: □ Septrintab 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: 24d. TB Treatment: □ None Reason for stop/change/re-dose:	mg ml ml st Toxic s/day or Weig Sta Comp	_ml Tabs 20 30 mg g _ml 0 Tabsn Tabsn tabsn to control (Specify) 	Tabs m ng ntinue Regin / D Co Toxicity Other Change Foxicity (Spe	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 0 Other: weight Change Reg Weight Change apsone mg/day ntinue INH R (Specify) 0 to Continuation 0 cify) Weight	□Syrup : □Syrup Powder imen □ Re □ Other e-dose Acti rug Dose: □ ontinue Regin oht Change	mgmgmgmgmgmgmg	mlTa mlTa T; Stop  NH mg/day Re-dose	bs m bs m abs n
d4T (1mg/kg): : □ Tabs     AZT: (180mg/m2): □ Syrup     NVP: □ Syrupmg     EFV: □ Syrupmg 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose: 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: 24d. TB Treatment: □ None Reason for stop/change/re-dose:	mg ml ml st Toxic s/day or Weig Sta Comp	_ml Tabs 20 30 mg g _ml 0 Tabsn Tabsn tabsn to control (Specify) 	Tabs m ng ntinue Regin / D Co Toxicity Other Change Foxicity (Spe	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 0 Other: weight Change Reg Weight Change apsone mg/day ntinue INH R (Specify) 0 to Continuation 0 cify) Weight	□Syrup : □Syrup Powder imen □ Re □ Other e-dose Acti rug Dose: □ ontinue Regin oht Change	mgmgmgmgmgmgmg	mlTa mlTa T; Stop  NH mg/day Re-dose	bs m bs m abs n
d4T (1mg/kg): : □ Tabs     AZT: (180mg/m2): □ Syrup     NVP: □ Syrupmg     EFV: □ Syrupmg 24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose New Drugs: □ Septrintab 24c. TB Prophylaxis: □ None Reason for stop/change/re-dose: 24d. TB Treatment: □ None Reason for stop/change/re-dose New Drugs: □ Rifatertab     □ Streptomycintab     □ Streptomycintab     □ Streptomycin	mgm ml ml ml Stat ::Toxic s/day or  Uwig Stat ::Comp s/day mg	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art Co ty (Specify) _ ml/day Start INH leted ht Change rt Induction oleted 1 Rifinah Rifinah	Tabs m ng ntinue Regin / D Co Toxicity Other Change Foxicity (Spe	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 0 Other: weight Change Reg Weight Change apsone mg/day ntinue INH R (Specify) 0 to Continuation 0 cify) Weight	□Syrup : □Syrup Powder imen □ Re □ Other e-dose Acti rug Dose: □ ontinue Regin oht Change	mgmgmgmgmgmgmg	mlTa mlTa T; Stop  NH mg/day Re-dose	bs m bs m abs n
d4T (1mg/kg): : □ Tabs     AZT: (180mg/m2): □ Syrup     NVP: □ Syrup mg     EFV: □ Syrup mg     24b. PCP Prophylaxis: □ None     Reason for stop/change/re-dose     New Drugs: □ Septrin tab     24c. TB Prophylaxis: □ None     Reason for stop/change/re-dose     24d. TB Treatment: □ None     Reason for stop/change/re-dose     None     Reason for stop/change/re-dose     Steptomycin     Steptomycin     24e. Immunizations Ordered T	mg 15 m ml St Toxic s/day or Weig Sta Comp Weig Sta comp s/day mg oday:	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art Co ty (Specify) _ml/day Start INH leted ht Change rt Induction bleted 1 Rifinah_ 	Tabs m ng ntinue Regin Co	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Weight NH mg	□Syrup : □Syrup powder immen □ Re □ Other e-dose Acti rug Dose: □ ontinue Regin ght Change tabs/day	mgmgmgmgmgmgmg	mlTa mlTa T; Stop  NH mg/day Re-dose	bs m bs m abs n
d4T (1mg/kg): : □ Tabs     AZT: (180mg/m2): □ Syrup     NVP: □ Syrup mg     EFV: □ Syrup mg     24b. PCP Prophylaxis: □ None     Reason for stop/change/re-dose     New Drugs: □ Septrin tab     24c. TB Prophylaxis: □ None     Reason for stop/change/re-dose     24d. TB Treatment: □ None     Reason for stop/change/re-dose     None     Reason for stop/change/re-dose     Steptomycin     Steptomycin     24e. Immunizations Ordered T	mg 15 m ml St Toxic s/day or Weig Sta Comp Weig Sta comp s/day mg oday:	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art Co ty (Specify) _ml/day Start INH leted ht Change rt Induction bleted 1 Rifinah_ 	Tabs m ng ntinue Regin Co	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Weight NH mg	□Syrup : □Syrup powder immen □ Re □ Other e-dose Acti rug Dose: □ ontinue Regin ght Change tabs/day	mgmgmgmgmgmgmg	mlTa mlTa T; Stop  NH mg/day Re-dose	bs m bs m abs n
d4T (1mg/kg): : □ Tabs     AZT: (180mg/m2): □ Syrup     NVP: □ Syrup mg     EFV: □ Syrup mg     24b. PCP Prophylaxis: □ None Reason for stop/change/re-dose New Drugs: □ Septrin tab     24c. TB Prophylaxis: □ None Reason for stop/change/re-dose:     24d. TB Treatment: □ None Reason for stop/change/re-dose New Drugs: □ Rifatertab     □ Streptomycin     24e. Immunizations Ordered T	mg 15 m ml St Toxic s/day or Weig Sta Comp Weig Sta comp s/day mg oday:	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art Co ty (Specify) _ml/day Start INH leted ht Change rt Induction bleted 1 Rifinah_ 	Tabs m ng ntinue Regin Co	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Weight NH mg	□Syrup : □Syrup powder immen □ Re □ Other e-dose Acti rug Dose: □ ontinue Regin ght Change tabs/day	mgng	_ml ITa _ml ITa ITa Stop 	bs m bs m abs n
□ d4T (1mg/kg):       : □ Tabs         □ AZT: (180mg/m2):       □ Syrup         □ NVP:       □ Syrup       mg         □ EFV:       □ Syrup       mg         24b. PCP Prophylaxis:       □ None         Reason for stop/change/re-dose       None         New Drugs:       □ Septrintab         24c. TB Prophylaxis:       □ None         Reason for stop/change/re-dose       None         Reason for stop/change/re-dose       None         Reason for stop/change/re-dose       Streptomycin	mgm mimimi mimi mi sictions	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art 0 Co ity (Specify) ml/day Start INH leted ht Change tt Induction oleted 1 Rifinah Rifampie Dose#:0 Dose#:0	Tabsm ngm ntinue Regin Co Toxicity Change Toxicity (Spe tabs/d: cinmg 1 23 1 23 1 23	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: o Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C cify) Weight ay Rifafour BCG Measles Polio	□Syrup □ Syrup □ Powder pimen □ Re □ Other e-dose □ Actit rug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 Dose#: □ 1	mg	mlTa mlTa Ta Stop  INH mg/day Re-dose er  mbutol zinamide	bs m bs m abs n
□ d4T (1mg/kg):       : □ Tabs         □ A2T: (180mg/m2):       Syrup         □ NVP:       □ Syrup       mg         □ EFV:       □ Syrup       mg         24b. PCP Prophylaxis:       None         Reason for stop/change/re-dose         New Drugs:       □ Septrin       tab         24c. TB Prophylaxis:       None         Reason for stop/change/re-dose         24d. TB Treatment:       None         Reason for stop/change/re-dose         Nove Drugs:       Rifatertab         □ Streptomycin       24e.         Pentavalent       □         Pentavalent       □         24f. Feeding plan:       □ Breast        Other liau       □	mgm mm mm 	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art Co ty (Specify) _ml/day Start INH leted ht Change rt Induction leted 1 Rifinah_ Rifiampic Dose#:0 Dose#	Tabs m mg ntinue Regir Concer Change Toxicity (Spe tabs/d: cinmg 1 _ 2 _ 3 1 _	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Weight Rifafour BCG BCG Polio Solid food	□Syrup □Syrup □Powder pimen □ Re □ Other e-dose trug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □Costatoe	mgmgmgmgmgmgmgmgmgmgmgmgmg	ml	bs m bs m abs n
□ d4T (1mg/kg):       : □ Tabs         □ A2T: (180mg/m2):       Syrup         □ NVP:       □ Syrup       mg         □ EFV:       □ Syrup       mg         24b. PCP Prophylaxis:       None         Reason for stop/change/re-dose         New Drugs:       □ Septrin       tab         24c. TB Prophylaxis:       None         Reason for stop/change/re-dose         24d. TB Treatment:       None         Reason for stop/change/re-dose         Nove Drugs:       Rifatertab         □ Streptomycin       24e.         Pentavalent       □         Pentavalent       □         24f. Feeding plan:       □ Breast        Other liau       □	mgm mm mm 	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art Co ty (Specify) _ml/day Start INH leted ht Change rt Induction leted 1 Rifinah_ Rifiampic Dose#:0 Dose#	Tabs m mg ntinue Regir Concer Change Toxicity (Spe tabs/d: cinmg 1 _ 2 _ 3 1 _	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Weight Rifafour BCG BCG Polio Solid food	□Syrup □Syrup □Powder pimen □ Re □ Other e-dose trug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □Costatoe	mgmgmgmgmgmgmgmgmgmgmgmgmg	ml	bs m bs m abs n
□ d4T (1mg/kg):       : □ Tabs         □ AZT: (180mg/m2):       : Syrup         □ NVP:       : Syrup       mg         □ EFV:       : Syrup       mg         24b. PCP Prophylaxis:       : None         Reason for stop/change/re-dose         New Drugs:       : Septrin       tab         24c. TB Prophylaxis:       : None         Reason for stop/change/re-dose         24d. TB Treatment:       : None         Reason for stop/change/re-dose         None       : Steptomycin         24e. Immunizations Ordered T         Pentavalent       : Pentavalent         • Pentavalent       : Breast	mgm mm mm 	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art Co ty (Specify) ml/day Start INH leted ht Change rt Induction leted 1 Rifinah_ Rifiampic Dose#:0 Dose#:0 Dose#:0 Age Affor	Tabs m mg ntinue Regir Concerce Toxicity (Spe  Change Toxicity (Spe  Change Toxicity (Spe  Change Toxicity (Spe  1 0 2 0 3 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Weight Rifafour BCG Measles Polio Solid food	□Syrup □Syrup □Powder pimen □ Re □ Other e-dose trug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □Costatoe	mgmgmgmgmgmgmgmgmgmgmgmgmg	ml	bs m bs m abs n
□ d4T (1mg/kg):       □ Tabs         □ A2T: (180mg/m2):       □ Syrup         □ NVP:       □ Syrup       mg         □ EFV:       □ Syrup       mg         24b. PCP Prophylaxis:       □ None         Reason for stop/change/re-dose         New Drugs:       □ Septrin       tab         24c. TB Prophylaxis:       □ None         Reason for stop/change/re-dose         24d. TB Treatment:       □ None         Reason for stop/change/re-dose         ○ Steptomycin       □         24e. Immunizations Ordered T       □         Pentavalent       □         □ Pentavalent       □         □ Other liqu       □         If this is a change, reason for chiz       24g. Other Drugs Started or R	mgm mm mm 	_ml Tabs 20 30 mg 20 30 mg 20 ml 0 Tabsn Tabsn Tabsn Tabsn Tabsn tabbsn ta	Tabs m ng ntinue Regin Co _	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: men Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Q Rifafour INH mg BCG BCG Polio Solid food Intolerance Othe	□Syrup □Syrup □Powder pimen □ Re □ Other e-dose trug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □Costatoe	mgmgmgmgmgmgmgmgmgmgmgmgmg	ml  _Ta ml  _Ta	bs m bs m abs m Stop mg mg
□       d4T (1mg/kg): : □       Tabs         □       AZT: (180mg/m2): □       Syrup         □       NVP: □       Syrup       mg         □       EFV: □       Syrup       mg         24b. PCP Prophylaxis: □       None         Reason for stop/change/re-dose         New Drugs: □       Septrin       tab         24c. TB Prophylaxis: □       None         Reason for stop/change/re-dose         24d. TB Treatment: □       None         Reason for stop/change/re-dose         New Drugs: □       Rifater	mgm mm mm 	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art Co ty (Specify) ml/day Start INH leted ht Change rt Induction leted 1 Rifinah_ Rifiampic Dose#:0 Dose#:0 Dose#:0 Age Affor	Tabs m ng ntinue Regin Co 	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Weight Rifafour BCG Measles Polio Solid food	□Syrup □Syrup □Powder pimen □ Re □ Other e-dose trug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □Costatoe	mgmgmgmgmgmgmgmgmgmgmgmgmg	ml	bs m bs m abs m Stop mg mg
□ d4T (1mg/kg):       : □ Tabs         □ A2T: (180mg/m2):       Syrup         □ NVP:       □ Syrup       mg	mgm mm mm 	_ml Tabs 20 30 mg 20 30 mg 20 ml 0 Tabsn Tabsn Tabsn Tabsn Tabsn tabbsn ta	Tabs m ng ntinue Regin Co 	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: men Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Q Rifafour INH mg BCG BCG Polio Solid food Intolerance Othe	□Syrup □Syrup □Powder pimen □ Re □ Other e-dose trug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □Costatoe	mgmgmgmgmgmgmgmgmgmgmgmgmg	_ml ITa _ml ITa ITa ITa ITa ITa ITa ITa ITa ITa ITa	bsm bsm absm Stop mg/day mg
<ul> <li>d4T (1mg/kg): : □ Tabs</li> <li>AZT: (180mg/m2): □ Syrup</li> <li>NVP: □ Syrup mg_</li> <li>EFV: □ Syrup mg_</li> <li>24b. PCP Prophylaxis: □ None</li> <li>Reason for stop/change/re-dose</li> <li>New Drugs: □ Septrin tab</li> <li>24c. TB Prophylaxis: □ None</li> <li>Reason for stop/change/re-dose:</li> <li>24d. TB Treatment: □ None</li> <li>Reason for stop/change/re-dose:</li> <li>24e. Immunizations Ordered T</li> <li>□ Pentavalent</li> <li>□ Pentavalent</li> <li>□ Other liqu</li> <li>It this is a change, reason for ch:</li> <li>24g. Other Drugs Started or R</li> <li>Drug</li> <li>1.</li> <li>2.</li> <li>3.</li> </ul>	mgm mm mm 	_ml Tabs 20 30 mg 20 30 mg 20 ml 0 Tabsn Tabsn Tabsn Tabsn Tabsn tabbsn tabbsn tabsn tabsn tabsn ta	Tabs m ng ntinue Regin Co 	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: men Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Q Rifafour INH mg BCG BCG Polio Solid food Intolerance Othe	□Syrup □Syrup □Powder pimen □ Re □ Other e-dose trug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □Costatoe	mgmgmgmgmgmgmgmgmgmgmgmgmg	ml  Gra ml  Gra Gra Gra Gra Gra Gra Gra Gra	bsm bsm absm mg/day mg mg
<ul> <li>d4T (1mg/kg): : □ Tabs</li> <li>AZT: (180mg/m2): □ Syrup</li> <li>MVP: □ Syrup mg_</li> <li>EFV: □ Syrup mg_</li> <li>24b. PCP Prophylaxis: □ None</li> <li>Reason for stop/change/re-dose</li> <li>New Drugs: □ Septrin tab</li> <li>24c. TB Prophylaxis: □ None</li> <li>Reason for stop/change/re-dose</li> <li>24d. TB Treatment: □ None</li> <li>Reason for stop/change/re-dose</li> <li>New Drugs: □ Rifatertab</li> <li>□ Streptomycin_</li> <li>24e. Immunizations Ordered T</li> <li>□ Pentavalent □</li> <li>□ Pentavalent □</li> <li>□ Other liqu</li> <li>If this is a change, reason for ch:</li> <li>24g. Other Drugs Started or R</li> <li>Drug</li> <li>1.</li> <li>2.</li> </ul>	mgm mm mm 	_ml Tabs 20 30 mg 20 30 mg 20 ml 0 Tabsn Tabsn Tabsn Tabsn Tabsn tabbsn tabbsn tabsn tabsn tabsn ta	Tabs m ng ntinue Regin Co 	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: men Change Reg Weight Change apsone mg/day ntinue INH R (Specify) to Continuation C cify) Q Rifafour INH mg BCG BCG Polio Solid food Intolerance Othe	□Syrup □Syrup □Powder pimen □ Re □ Other e-dose trug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □Costatoe	mgmgmgmgmgmgmgmgmgmgmgmgmg	ml	bsm bsm absm mg/day mg mg
□       d4T (1mg/kg): : □       Tabs         □       AZT: (180mg/m2): □       Syrup         □       NVP: □       Syrup       mg         □       EFV: □       Syrup       mg         24b. PCP Prophylaxis: □       None         Reason for stop/change/re-dose         New Drugs: □       Septrin tab         24c. TB Prophylaxis: □       None         Reason for stop/change/re-dose         24d. TB Treatment: □       None         Reason for stop/change/re-dose         24d. TB Treatment: □       None         Reason for stop/change/re-dose         24d. TB Treatment: □       None         Reason for stop/change/re-dose         Nore       Streptomycin         24e. Immunizations Ordered T         □       Pentavalent         □       Pentavalent         □       Other Drugs Started or R         Ortug       1.         2.       3.         25. Tests Ordered:       □         □       Full Haemogram	mgm mm mm m 	_ml Tabs 20 30 mg 20 30 mg g _ml i Tabs _mg art Co ity (Specify) _ml/day Start INH leted ht Change rt Induction leted 1 Rifinah Rifampic Dose#: Dose#	Tabs m ng ntinue Regir Co 	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C cify)Q Rifafour BCG Measles Polio Solid food Intolerance Othe Freq & Duration	□Syrup □Syrup □Syrup □Other e-dose a-dote trug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □Cose#: □Cose#: □Cose#	mgmgmgmgmgmgmgdoses Stopp we TB INH 0 Othe Etha Othe Etha 2 2 w/s/Aniii	ml	bsm bsm absm mg/day mg mg
□       d4T (1mg/kg): : □       Tabs         □       AZT: (180mg/m2): □       Syrup         □       NVP: □       Syrup       mg	mgm mm mm 	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art 0 Co ity (Specify) ml/day Start INH leted ht Change rt Induction bleted 1 Rifinah Rifinah Rifinah Bose#: Doso: Dose#: Dose#: Dose#: Dose#:	Tabs m ng ntinue Regir Co 	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C cify)Q Rifafour BCG Measles Polio Solid food Intolerance Othe Freq & Duration	□Syrup □ Syrup □ Powder immen □ Re □ Other □ Other e-dose □ Acti rug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □ Co (ugali, potatoe rr(Specify):	mgmgmgmgmgmgmgdoses Stopp we TB INH 0 the 1 the 2 x w's/Aniii	ml	bsm bsm absm mg/day mg mg
□       d4T (1mg/kg):       :       □       Tabs         □       AZT: (180mg/m2):       □       Syrup       mg         □       NVP:       □       Syrup       mg         □       EFV:       □       Syrup       mg         24b. PCP Prophylaxis:       □       None         Reason for stop/change/re-dose:       None         Note:       □       Septrin       tab         24c. TB Prophylaxis::       □       None         Reason for stop/change/re-dose:       □       None         24d. TB Treatment:       □       None         Reason for stop/change/re-dose:       □       None         24d. TB Treatment:       □       None         Reason for stop/change/re-dose:       □       Ib         24d. TB Treatment:       □       None         Reason for stop/change/re-dose:       □       Ib         □       Pentavalent:       □       Ib         □       Pentavalent:       □       □         □       Pentavalent:       □       □         □       Pentavalent:       □       □         □       Pentavalent:       □       □         24f. Fe	mgm mlml mlmlml mlml ssta stay gsta stay mg stay mg stay mg stay mg stay mg stay t	_ml Tabs 20 30 mg g_ml 0 17abs _mg art 0 Co ty (Specify) _ ml/day Start INH leted ht Change rt Induction Dieted 1 Rifiampic 0 Rifiampic 0 Sos#: 0 Dose#: 0 D	Tabs m ng ntinue Regin D. Coo Toxicity Other Change Toxicity (Spe tabs/d: mg 1 2 3 1 _	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: o Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C cify)Q Weight ay Rifafour BCG Measles Polio BCG Measles Polio Solid food Intolerance Othe Freg & Duration	Syrup	mgmgmgmgmgmgmgmgmgstop we TBstop _	_ml Ta _ml Ta _ml Ta _Ta _Ta _Ta _Ta _Ta _Ta _Ta _Ta _Ta _	bsm bsm absm stop mg/day mg
<ul> <li>d4T (1mg/kg): : □ Tabs</li> <li>AZT: (180mg/m2): □ Syrup</li> <li>MVP: □ Syrup mg_</li> <li>EFV: □ Syrup mg_</li> <li>24b. PCP Prophylaxis: □ None</li> <li>Reason for stop/change/re-dose</li> <li>New Drugs: □ Septrin tab</li> <li>24c. TB Prophylaxis: □ None</li> <li>Reason for stop/change/re-dose:</li> <li>24d. TB Treatment: □ None</li> <li>Reason for stop/change/re-dose</li> <li>New Drugs: □ Streptomyoin</li> <li>24e. Immunizations Ordered T</li> <li>Pentavalent vaccine</li> <li>24f. Feeding plan: □ Breast □</li> <li>Other Drug</li> <li>1.</li> <li>2.</li> <li>3.</li> <li>25. Tests Ordered:</li> <li>Full Haemogram □ Hgb</li> <li>HIV Elisa □ HIV D</li> <li>26. Referrals:</li> <li>None □ TB treatment</li> </ul>	mgm mm mm	_ml Tabs 20 30 mg g _ml 0 17abs _mg art 0 Co ty (Specify) _ ml/day Start INH leted ht Change rt Induction 0 leted 1 Rifinah_ Rifinah_ 0 Rifinah_ 0 Rifinah	Tabs m mg intinue Regin continue Regin co	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C coffy)Q Weight to Continuation C coffy)Q Weight BCG BCG BCG BCG BCG Solid food Intolerance Othe Freq & Duration CD4 Panel CXR	□Syrup □ Syrup □ Powder imen □ Re □ Other e-dose a Acti rug Dose: □ ontinue Regin ght Change tabs/day Dose#: □ 1 □ Co (ugali, potatoe r(Specify): □ Viral Load □ Other (Speci al support	mgmgmgmgmgmgmgmgmgmgs Stopp ve TB Stopp ve TB Stophase Stopha	ml	bsm bsm absm stop mg/day mg
□ d4T (1mg/kg):       □ Tabs         □ AZT: (180mg/m2):       □ Syrup         □ NVP:       □ Syrup       mg         □ EFV:       □ Syrup       mg         24b. PCP Prophylaxis:       □ None         Reason for stop/change/re-dose         New Drugs:       □ Septrin       tab         24c. TB Prophylaxis:       □ None         Reason for stop/change/re-dose:         24d. TB Treatment:       □ None         Reason for stop/change/re-dose:         24d. TB Treatment:       □ None         Reason for stop/change/re-dose:         24d. TB Treatment:       □ None         □ Steptomycin       □         24e. Immunizations Ordered T       □         Pentavalent       □         □ Pentavalent       □         □ Other Drugs Started or R       □         Drug       □         1.       □         2.       □         3.       □         25. Tests Ordered:       □         □ Full Haemogram       □ Hgb         □ HIV Elisa       □ HIV D         26. Referrals:       □ None         □ None       □ TB treatment <td>mgm mmlm mlm mgsta s</td> <td>_ml Tabs 20 30 mg g _ml 0 Tabs _mg art 0 Co ity (Specify) _ ml/day Start INH leted 1 1 Rifinah _ Rifinah _ Rifinah _ Rifinah _ Dose#: 0 Dose#: 0 Do</td> <td>Tabs m mg ntinue Regin  Co  Co</td> <td>ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C cify)Q Weight to Continuation C cify)Q Weight BCG Weasles Polio BCG Others Formula Solid food Intolerance Other Freq &amp; Duration CD4 Panel CXR</td> <td>□Syrup □Syrup □Syrup □Other □Other □Acti rug Dose: □ ontinue Regin ght Change tabs/day Dose#: 1 □Co (ugali, potatoe rr(Specify): □Viral Load □Other (Spec al support □OVC</td> <td>mgmgmgmgmgmgmgmgmgs Stopp er TB INH term = 0 Othe = Etha = Pyra = 2 // s/s/ana = 0 // s, bana = 0 // s, bana</td> <td>ml</td> <td>bs m bs m abs m mg/day mg mg </td>	mgm mmlm mlm mgsta s	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art 0 Co ity (Specify) _ ml/day Start INH leted 1 1 Rifinah _ Rifinah _ Rifinah _ Rifinah _ Dose#: 0 Dose#: 0 Do	Tabs m mg ntinue Regin Co	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C cify)Q Weight to Continuation C cify)Q Weight BCG Weasles Polio BCG Others Formula Solid food Intolerance Other Freq & Duration CD4 Panel CXR	□Syrup □Syrup □Syrup □Other □Other □Acti rug Dose: □ ontinue Regin ght Change tabs/day Dose#: 1 □Co (ugali, potatoe rr(Specify): □Viral Load □Other (Spec al support □OVC	mgmgmgmgmgmgmgmgmgs Stopp er TB INH term = 0 Othe = Etha = Pyra = 2 // s/s/ana = 0 // s, bana	ml	bs m bs m abs m mg/day mg mg 
□ d4T (1mg/kg): : □ Tabs         □ A2T: (180mg/m2): □ Syrup         □ NVP: □ Syrup mg         □ EFV: □ Syrup mg         24b. PCP Prophylaxis: □ None         Reason for stop/change/re-dose         New Drugs: □ Septrin tab         24c. TB Prophylaxis: □ None         Reason for stop/change/re-dose         24d. TB Treatment: □ None         Reason for stop/change/re-dose         □ Other Stop/change/re-dose         □ Pentavalent         □ Pentavalent         □ Pentavalent         □ Pentavalent         □ Other Drugs Started or R         Drug         1.         2.         3.         25. Tests Ordered:         □ Full Haemogram       □ Hgb         □ HIV Elisa       □ HIV D         26. Referrals:       □ None         □ None       □ TB treatment         □ Psychosocial counseling       □ Inpatie	mgm mmlm mlm mgsta s	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art 0 Co ity (Specify) _ ml/day Start INH leted 1 1 Rifinah _ Rifinah _ Rifinah _ Rifinah _ Dose#: 0 Dose#: 0 Do	Tabs m mg ntinue Regin Co	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C cify)Q Weight to Continuation C cify)Q Weight BCG Weasles Polio BCG Others Formula Solid food Intolerance Other Freq & Duration CD4 Panel CXR	□Syrup □Syrup □Syrup □Other □Other □Acti rug Dose: □ ontinue Regin ght Change tabs/day Dose#: 1 □Co (ugali, potatoe rr(Specify): □Viral Load □Other (Spec al support □OVC	mgmgmgmgmgmgmgmgmgs Stopp er TB INH term = 0 Othe = Etha = Pyra = 2 // s/s/ana = 0 // s, bana	ml	bs m bs m abs m mg/day mg mg 
□       d4T (1mg/kg):       :       □       Tabs         □       AZT: (180mg/m2):       Syrup	mgm mm mm mm Sta Stay     	_ml Tabs 20 30 mg 20 30 mg 30 ml 1 Tabs _mg at Co ity (Specify) ml/day Start INH leted ht Change rt Induction leted 1 Rifiampic None Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Creal gram A upport Servi H Health	Tabs m mg intinue Regin D. Co D. Co Co Toxicity Change Toxicity (Spe tabs/d: mg 1 2 3 1 3	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C cify) Weight NHmg BCG Measles Polio BCG Measles Polio Solid food Intolerance Cthe Freq & Duration CCD4 Panel CXR	□Syrup □Syrup □Syrup □Other □ontinue Regin ght Change tabs/day Dose#: 1 Dose#: 1 □Con (ugali, potatoe r(Specify): □Viral Load □Other (Specify) □Viral Load □Other (Specify) □Other (Specify) □	mgmgmgmgmgmgmgmgmgs Stopp er TB INH term = 0 Othe = Etha = Pyra = 2 // s/s/ana = 0 // s, bana	ml	bsm bsm absm Stop mg 
□       d4T (1mg/kg): : □       Tabs         □       AZT: (180mg/m2): □       Syrup         □       NVP: □       Syrup       mg         □       EFV: □       Syrup       mg         24b. PCP Prophylaxis: □       None         Reason for stop/change/re-dose         New Drugs: □       Septrin tab         24c. TB Prophylaxis: □       None         Reason for stop/change/re-dose         24d. TB Treatment: □       None         Reason for stop/change/re-dose         24d. TB Treatment: □       None         Reason for stop/change/re-dose         24d. TB Treatment: □       None         Reason for stop/change/re-dose         None       Steptomycin         24e. Immunizations Ordered T       □         Pentavalent       □         Pentavalent       □         Pentavalent       □         Pentavalent       □         Qother Drugs Started or R       Orther liqu         If this is a change, reason for cha       24g. Other Drugs Started or R         Drug       □       □         1.       □       □         25. Tests Ordered:       □         □       Psychosocial counseling	mgm mm mm m 	_ml Tabs 20 30 mg g _ml 0 Tabs _mg art 0 Co ity (Specify) _ ml/day Start INH leted 1 1 Rifinah _ Rifinah _ Rifinah _ Rifinah _ Dose#: 0 Dose#: 0 Do	Tabs m mg intinue Regin D. Co D. Co Co Toxicity Change Toxicity (Spe tabs/d: mg 1 2 3 1	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C cify)Q Weight to Continuation C cify)Q Weight BCG Weasles Polio BCG Others Formula Solid food Intolerance Other Freq & Duration CD4 Panel CXR	□Syrup □Syrup □Syrup □Other □ontinue Regin ght Change tabs/day Dose#: 1 Dose#: 1 □Con (ugali, potatoe r(Specify): □Viral Load □Other (Specify) □Viral Load □Other (Specify) □Other (Specify) □	mgmgmgmgmgmgmgmgmgs Stopp er TB INH term = 0 Othe = Etha = Pyra = 2 // s/s/ana = 0 // s, bana	ml	bsm bsm absm absm mg/day mg Dose       
□       d4T (1mg/kg):       :       □       Tabs         □       AZT: (180mg/m2):       Syrup	mgm mm mm m 	_ml Tabs 20 30 mg 20 30 mg 30 ml 1 Tabs _mg at Co ity (Specify) ml/day Start INH leted ht Change rt Induction leted 1 Rifiampic None Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Dose#: Creal gram A upport Servi H Health	Tabs m mg intinue Regin D. Co D. Co Co Toxicity Change Toxicity (Spe tabs/d: mg 1 2 3 1	ABC (8mg/kg): g DDI (100mg/m2 Nelfinavir: 1 Other: nen Change Reg Weight Change apsone mg/day ntinue INH R (Specify)D to Continuation C cify) Weight NHmg BCG Measles Polio BCG Measles Polio Solid food Intolerance Cthe Freq & Duration CCD4 Panel CXR	□Syrup □Syrup □Syrup □Other □ontinue Regin ght Change tabs/day Dose#: 1 Dose#: 1 □Con (ugali, potatoe r(Specify): □Viral Load □Other (Specify) □Viral Load □Other (Specify) □Other (Specify) □	mgmgmgmgmgmgmgmgmgs Stopp er TB INH term = 0 Othe = Etha = Pyra = 2 // s/s/ana = 0 // s, bana	ml	bsm bsm absm absm g mg mg      

# Appendix B: AMPATH Rural Health Centre Pediatric Clinical Encounter Form

	3 names	– given,	middle	e, family	):		2. AMR	S ID:		Today's I 3. Old MM	IRS ID:	4. H	CT ID:	
5. Age:	Yrs		Mo		Days _		6. Sex:		] F	7. Marital	Status: 🗆	S DM		V 🗆 S
8. Next of	Kin:				9. P	hone #:				10. Occup	ation:			
11. Clinic	Child< 5	Child 5+	Adult	FamPlan	STI	Chest/TB	Dental	ENT	Eye	PhysT	Occ T	Plaster	Psych	Othe
New														
Return											-	-		-
2. Main F										Du	ation of ill	ness (days	i)	_
None (														
Prior Care		Problem	n: 🗆 N	one	Self-	medicate	d D1	raditiona	l healer	Priva	te Pharma	acy 🗆	CHW	
3. Vital S BP:		Pulse			Weight	-	ka H	eight:	cm	Temp	•	C Head	circ	cm
/isual Acu												o neau		
	olod on H	IV today	2· □	Yes 🗆	No 🗆	]N/A		15 Tes	ted for H	IIV today?:	Vee		1N/A	
<ol> <li>Couns</li> </ol>		iiv iooay						10.100		es, record				
Family Pla	anning C ception (c	linic Dat	a that ap		ondom:			FP #:	(If Y		Test resul	t in test se	ction)	🗆 pi
amily PI: 6. Contra Other:_ Paediatric 7. Under 9. Dange (Yes:	anning C ception ( Clinic D weight? or Signs t Unable to Other urg	linic Dat check all data yes this visit o drink or gent sign Ear Prot	that ap	ply): c Notes: No Yes c feed c ding imm	ondom:	s 🗆 IU	D 🗆 si	FP #: , terilization 8. Issued 1 Has had	(If Y	es, record	Test resul	gm De	poProvera	□ p
amily PI: 6. Contra Other: Paediatric 7. Under 9. Dange (Yes: Additiona	anning C aception ( ception ( ception ( weight? or Signs t Unable to Other urg I Comme	linic Dat check all ata Yes this visit o drink or gent sign Ear Prot ents:	that ap	ply): c Notes: No Yes c feed c ding imm	ondom:	s 🗆 IU	D 🗆 si	FP #: , terilization 8. Issued 1 Has had	(If Y	tural FP [	Test resul	gm De	poProvera	_ p
amily Pl: 6. Contra Other:_ Paediatric 7. Under 9. Dange Yes: Charles Milliona	anning C iception (i ception (i ception (i weight? or Signs t Unable to Other urg l Comme nizations	linic Dat check all ata Yes this visit o drink or gent sign Ear Prot ints: Given T	that ap	ply): c Notes: No Yes c feed c ding imm	3 No I Vomiti nediate	s D IU	D S	FP #: , terilization 8. Issued 1 Has had lough or o	(If Y n na with ITN d convuls difficulty	tural FP [ tural FP [ today? sions ] L breathing	Test resul	gm De	poProvera	
amily Pl: 6. Contra Other:_ Paediatric 7. Under 9. Dange (Yes: _ Additiona Additiona	anning C iception (i ception (i ception (i weight? or Signs t Unable to Other urg l Comme nizations	linic Dat check all ata Yes this visit o drink or gent sign Ear Prot ints: Given T	that ap	ply): c Notes: No Yes c feed c ding imm	ondom:	s D IU	D 🗆 si	FP #: , terilization 8. Issued 1 Has had	(If Y	tural FP C I today? sions C L breathing	Test resul	gm De	poProvera	Reva
amily Pl: 6. Contra Other: Paediatric 7. Under 9. Dange Yes: Quantum Yentavaler Polio	anning C iception (i e Clinic D weight? or Signs t Unable to Other urg l Comme nizations nt (DTP-H	linic Dat check all data Yes this visit o drink or gent sign Ear Prot ints: Given T	that ap	ply): C Notes: No Yes C feed C ding imm Other:	3 No I Vomiti nediate	s 🗆 IU	D S	FP #: , terilization 8. Issued 1 Has had lough or o	(If Y n	tural FP C I today? sions C L breathing	Test resul	gm De	poProvera cious aver	
amily Pl: 6. Contra Other: aediatric 7. Under 9. Dange Yes: Contra 4. Contra 2. Contra 4. Contra 2. Contra	anning C iception (i e Clinic D weight? or Signs t Unable to Other urg other urg I Comme nizations nt (DTP-H ver	linic Dat check all ata yeat withis visit o drink or gent sign Ear Prot ents: Given T tepB-Hib	a that ap s ? ? 'oteast deman blem C	ply): C c Notes: No Yes C feed C ding imm Other: 0	3 No I Vomiti nediate	s 🗆 IU	D S	FP #: , terilization 8. Issued 1 Has had cough or o	(If Y n	I today? sions L breathing les titis A	Test resul	t in test ser gm  De No Uncons Dea  Fe	ction) poProvera	Reva 2
amily Pl: 6. Contra Other: aediatric 7. Under 9. Dange Yes: Yes: dditiona 0. Immur rentavaler folio fellow Fer Other:	anning C iception (i e Clinic D weight? or Signs t Unable to Other urg other urg I Comme nizations nt (DTP-H ver	linic Dat check all ata yeat bis visit o drink or gent sign Ear Prot onts: Given T tepB-Hib plete?	that ap	ply): c Notes: No Yes c feed c ding imm Other: 0	0 No 1 Vomiti nediate	s 🗆 IU	D   si   11 thing   12   2   2 	FP #: . terilization 8. Issued 1 Has had lough or o	(If Y n	tural FP C I today? sions D L breathing les titis A	Test resul	t in test see gm  De No Uncons Dea Fe	ction) poProvera	Reva 2 2
amily Pl: 6. Contra Other: Paediatric 7. Under 9. Dange f Yes: Contra Additiona Additiona 20. Immur Pentavaler Polio Yellow Fer Other: mmunizat	anning C iception (i ception (i ception (i ception (i weight? rr Signs t Unable to Other urg I Comme nizations nt (DTP-H ver	linic Dat check all ata yeat withis visit o drink or gent sign Ear Prot ents: Given T tepB-Hib	that ap	ply): C c Notes: No Yes C feed C ding imm Other: 0	3 No I Vomiti nediate	s 🗆 IU	D S	FP #: , terilization 8. Issued 1 Has had cough or o	(If Y n	tural FP C I today? sions D L breathing les titis A r Present? 41 4	Test resul	t in test ser gm  De No Uncons Dea  Fe	ction) poProvera	Reva 2 2 60
amily Pl: 6. Contra Other: Paediatric 7. Under 9. Dange f Yes: Charge Additiona 20. Immun 20. Imm	anning C ception ( ception ( ception ( weight? r Signs t Unable to Other urg I Comme nizations nt (DTP-H ver ions Commin A:	linic Dat check all ata yes this visit o drink or pent sign Ear Prot ents: Given T tepB-Hib plete? 6-11 mo	that ap	ply): c Notes: No Yes c feed c ding imm Other: 0 s N 12-17	I No I Vomiti nediate	s 🗆 IU	D S	FP #: terilization 8. Issued 1 Has had cough or of 3 3 3 3 3 3 3 3	(If Y n	tural FP C I today? sions D L breathing les titis A r Present? 41 4	Test resul	t in test see gm  De No Uncons Dea Fe	ction) poProvera ccious sver 0 1 1 1 54-59	Reva 2 2 60
amily Pl: 6. Contra Other: aediatric 7. Under 9. Dange (Yes: additiona 0. Immun entavaler folio fellow Fen Other: mmunizat 21. Vitar 2. Ancill	Anning C Ception ( Clinic D weight? or Signs t Unable to Other urg I Comme nizations nt (DTP-H ver ions Com min A: lary Servi	linic Dat check all ata yes this visit o drink or pent sign Ear Prot ents: Given T tepB-Hib plete? 6-11 mo	a that ap s C r breast deman blem	ply): c Notes: No Yes c feed c ding imm Other: 0 0 s N 12-17 mo	0 No 1 Vomiti nediate	s 🗆 IU	D S	FP #: terilization 8. Issued 1 Has had lough or of 3 3 3 3 1 E 30-35 mo	(If Y n	itural FP C itural FP C itoday? sions D L breathing les titis A r Present? 41 4: 0 1	Test resul	t in test see gm  De No Uncons Dea Fe	ction) poProvera ccious sver 0 1 1 1 54-59	Reva 2 2 60
amily Pl: 6. Contra Other:_ Paediatric 7. Under 9. Dange f Yes: 1. Additiona 0. Immuni 2. Immunizat 21. Vitar 2. Ancill Medica	Anning C Ception ( Ception ( C	linic Dat check all ata yeat bis visit o drink or gent sign Ear Prot ints: Given T HepB-Hib plete? 6-11 mo	a that ap s C r breast deman blem	ply): c Notes: No Yes c feed c ding imm Other: 0 0 s N 12-17 mo	0 No 1 Vomiti nediate	s IU ng every attention 23 2 o	D S	FP #: terilization 8. Issued 1 Has had lough or of 3 3 3 3 1 E 30-35 mo	(If Y in a name) with ITM d convuls difficulty BCG Meas Hepa BCG Sca 36- m	itural FP C itural FP C itoday? sions D L breathing les titis A r Present? 41 4: 0 1	Test resul	t in test see gm  De No Uncons Dea Fe	ction) poProvera ccious sver 0 1 1 1 54-59	Reva 2 2 60
Family Pla 16. Contra 10 Other:_ Paediatric 17. Under 19. Dange f Yes:	anning C iception (i ception (i ception (i ception (i r Signs t Unable to Other urg or Signs t Unable to Other urg I Comme nizations nt (DTP-H ver ions Com min A: I Exam I Clinic	linic Dat check all ata yest system yest sign Ear Prot outs: Given T tepB-Hib plete? 6-11 mo ices	a that ap s C r breast deman blem C r oday:	ply): C Notes: No Yes C feed C ding imm Other: Other: 0 0 s N No Yes C feed C ding imm Other: 0 0	I No Vomiti nediate	s IU ng every attention 23 2 o	D Si 11 thing C 2 C 2 4-29 mo	FP #: terilization 8. Issued 1 Has had cough or o a 3 3 3 3 	(If Y in a na with ITM d convuls difficulty BCG Meas Hepa CG Sca a convert CG Sca a convert co	itural FP C itural FP C itoday? sions D L breathing les titis A r Present? 41 4: 0 1	Test resul	t in test see gm  De No Uncons Dea Fe	ction) poProvera ccious sver 0 1 1 1 54-59	Reva 2

24. Test Results:			Blood suga	r.			Below	norma		nal	Above r	lemo		
VDRL:			-				DEIOW	nomia			LI AUUVEI	ornar		
Malaria smear:			Hgb:				HVS:		-					
Pregnancy Test: _			Blood Grou									ls ⊡Gi	VCs	ŝ
Widal Test:			Other:					□GP alysis	us ⊔ :⊡NAD	GPR	S			
Brucella Test: :	Aborteus		Mellitiues:				DPu	s cells	: 0+			+++		
Sputum for AFB:				. 3	rd	-		d cells otein: oar Pr		•	D++ C	]+++ ]+++ ]+++		
	Follow-up test:						<u> </u>	-						
HIV Rapid Test:	BIOLINE:		UNIGO	XLD:			Stoo	l Exan	n:			_		
Other (	):						Othe	r					_	
X- Ray 1:													_	
Ultrasound:													_	_
25. Diagnoses Th	is Visit:								New		Continue	Resolve	d	
1.												0		
2.										_			_	
3.								_		_			_	
4.					_	-	_						_	_
26. Drugs Given 1	This Visit					Dose		Freque	incy	Dur	ation	Picked	_	
1.										<u> </u>			_	
2.										<u> </u>			_	
3.													_	
4.													_	
5.										<u> </u>			_	
6.										<u> </u>			_	
7.							-							
27. Financial Office	1	Kabi		C	Walver	liner		Signati	ure:	Ksh		Exem		Waive
Item:		Ksh:		Exempt	waver	Item:				KSN		Exert	PR	many
													+	
													+	
28. Referrals														
Referrals:  None		Kapsabet D	Sistrict Hospit	al 🗆	Nandi I	Hills Dis	rict Ho:	spital	CO/Phys	ician				
C Admit	to Mosoriot Inpa	atient Unit	Other:											-
Reason for Referra	-													_
Followup Needed?	: Ves D N	lo Type	of Followup:					_	Nurse:					-
Return to Clinic: D									Provider	#:				_
Registration Fields	: Date of Birth:			_Fathe	er's Ful	I Name:	:							
Mother's Full Nam	8::				Guard	ian's Ful	I Name	c						
					May	t of Kin:								
Other person bring	ing patient:				NEX									